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Edited by J. H. NaismithAbstractSIRT1 is a NAD+-dependent deacetylase implicated in a
wide range of aging-related diseases and whose substrates
include key cellular regulators of a wide variety of central
signaling pathways.Resveratrol, a compound found ingrapes
and redwine, has been proposed tomediate beneficial health
effects through activation of SIRT1. A series of crystal
structures elucidates the conformational changes of the
human SIRT1 reaction cycle and establishes the molecular
mechanism of SIRT1 regulation.SIRT1 is a NAD+-dependent deacetylase that plays
important roles in many cellular processes. SIRT1
activity is uniquely controlled by a C-terminal
regulatory segment (CTR). Here we present crystal
structures of the catalytic domain of human SIRT1 in
complex with the CTR in an open apo form and a
closed conformation in complex with a cofactor and a
pseudo-substrate peptide. The catalytic domain
adopts the canonical sirtuin fold. The CTR forms a
β hairpin structure that complements the β sheet of
the NAD+-binding domain, covering an essentially
invariant hydrophobic surface. The apo form adopts
a distinct open conformation, in which the smaller
subdomain of SIRT1 undergoes a rotation with
respect to the larger NAD+-binding subdomain. A
biochemical analysis identifies key residues in the
active site, an inhibitory role for the CTR, and distinct
structural features of the CTR that mediate binding
and inhibition of the SIRT1 catalytic domain.
© 2013 The Authors. Published by Elsevier Ltd. All rights
reserved.Introduction
Sirtuins are a large family of protein-modifying
enzymes highly conserved throughout bacteria,atter © 2013 The Authors. Published by Elsearchaea, and eukaryotes. The founding member of
the sirtuin family, silent information regulator 2 (Sir2),
was first identified through a genetic screen in
Saccharomyces cerevisiae as necessary forvier Ltd. All rights reserved. J. Mol. Biol. (2014) 426, 526–541
527Structure of Human SIRT1silencing of the mating-type information locus, HM
[1]. Three additional sirtuin genes were subsequently
discovered inS. cerevisiae [2,3], the products of which
collectively act along with Sir2 to silence transcription
at telomeres and ribosomal DNA clusters as well as
HM loci [4–7]. Later work showed Sir2 and its
homologs to function primarily as NAD+-dependent
deacetylases [8–10], with specific family members
reported to possess mono-ADP ribosyl transferase
[11–16], demalonylase, or desuccinylase activity [17].
In the sirtuin deacetylation reaction, the substrate
acetyl group is transferred onto the ribose moiety of
NAD+, generating nicotinamide and 2′-O-acetyl-ade-
nosine diphosphoribose [18]. While the details of this
reaction are still a matter of debate, a proposed
mechanism that proceeds through an adenosine
diphosphoribose (ADPR)-peptidyl-imidate intermedi-
ate is consistent with available biochemical data [19].
Crystal structures of a number of sirtuin family
members have provided insight into substrate and
cofactor binding as well as catalysis [11,20–40].
The mammalian genome encodes seven different
sirtuins (SIRT1–SIRT7), with varying subcellular
localizations and chemical activities [17,41]. The
direct human homolog of S. cerevisiae Sir2 is
SIRT1. SIRT1 deacetylates a wide range of sub-
strates, including p53, NF-κB, FOXO transcription
factors, and PGC-1α, with roles in cellular processes
ranging from energy metabolism to cell survival [42].
As such, SIRT1 is implicated in awide range of human
diseases and is a prominent therapeutic target.
Despite progress over the last decade, relatively
little is known about the regulatory mechanism of
SIRT1. Like all sirtuins, SIRT1 is strongly inhibited by
nicotinamide through a base-exchange mechanism
that reforms cleaved NAD+ [43]. AROS (active
regulator of SIRT1) and DBC1 (deleted in breast
cancer 1) have been identified as endogenous
proteins that promote or inhibit SIRT1 activity,
respectively [44–46]. Additionally, various regions in
the long andmostly unstructuredN- andC-termini that
flank the SIRT1 catalytic domain have been shown to
affect SIRT1 deacetylation activity [47,48].
To shed light on the regulation of human SIRT1
activity, we have determined the crystal structure of
SIRT1 in complex with its C-terminal regulatory
segment (CTR) in its apo form and in a quaternary
complex with the NAD+ hydrolysis product ADPR
and a substrate-mimicking peptide at 2.65 Å and
1.85 Å resolution, respectively. The structures
reveal that the CTR binds at the lower edge of the
larger NAD+-binding domain, complementing the
central parallel β sheet of its Rossmann fold. The
substrate-bound closed state completely encapsu-
lates the cofactor and forms a binding site with a
hydrophobic tunnel for the substrate residue that
leads to a shielded active site in the interior of the
enzyme. The overall conformation and mode of
substrate binding confirm previous predictions ofhow human SIRT1 interacts with peptide substrates.
In the absence of bound cofactor and substrate, the
smaller domain of the SIRT1 catalytic domain under-
goes a striking ~25° rotation that is accompanied by
an ~15-Å shift of the residues of the domain,
generating a wide-open interdomain groove, while
the larger domain and CTR interface remain mostly
unchanged. A mutational analysis identifies key
residues for enzymatic activity of SIRT1 and supports
the previously proposed imidate reaction mechanism.
Further biochemical experiments establish an inhibi-
tory role for theCTRanddefine corresponding binding
and inhibitory regions. Our results provide a promising
avenue for the development of novel SIRT1 activators
that take advantage of the distinct features of the
catalytic domain–CTR interface.Results
Reconstitution of active SIRT1 and structure
determination
Our attempts to express various fragments of the
catalytic domain of Homo sapiens SIRT1 in bacteria
yielded protein prone to aggregation. Based on
previous findings that a C-terminal region is required
for SIRT1 activity [47,48], we generated a series of
expression constructs for various C-terminal frag-
ments that were tested for their ability to interact with
the catalytic domain. We identified residues 234–510
and residues 641–665 of the catalytic domain (CAT)
and theC-terminal regulatory segment (CTR), respec-
tively, which formed a heterodimeric complex as
determined by size-exclusion chromatography
(SEC) (Fig. 1a and b). Coexpression of the two
SIRT1 fragments greatly improved the solubility,
stability, and behavior of the catalytic domain in
solution (Tables S1 and S2). An analysis by SEC
coupled tomultiangle light scattering (MALS) revealed
that the heterodimer is monomeric in solution with a
measured molecular mass of 34.8 kDa (theoretical,
35.1 kDa) (Fig. 1c). We refer to this complex as the
SIRT1CAT·CTR heterodimer in the following text.
Crystals of the apo form of SIRT1CAT·CTR
appeared in the tetragonal space group P43212,
contained four copies of the heterodimer in the
asymmetric unit, and diffracted to 2.65 Å resolution.
We also obtained crystals of the SIRT1CAT·CTR
heterodimer in the presence of NAD+ in the trigonal
space group P3221 that diffracted to 1.85 Å and
contained one copy of the complex in the asymmetric
unit. Both structures were solved by single-wave-
length anomalous dispersion using anomalous X-ray
diffraction data obtained by taking advantage of the
endogenous bound Zn2+ ions. The final models
essentially contain all residues of both protein frag-
ments in the substrate- and cofactor-bound states and
Fig. 1. Biochemical analysis of the SIRT1CAT·CTR complex. (a) Domain structure. Blue, NAD+-binding domain; yellow,
helical module; green, Zn2+-binding module; red, pseudo-substrate peptide (T, tail); purple, C-terminal regulatory segment
(CTR); gray, predicted unstructured regions (U). The bars above the domain structuremark the crystallized fragments. (b) SEC
interaction analysis of SIRT1CAT with SUMO-CTR. The analyzed proteins and complexes are indicated in each gel-filtration
profile. For analysis of complex formation, the SUMO-CTR was mixed at approximately 2-fold molar excess of SIRT1CAT and
injected onto a Superdex 200 10/300 GL gel-filtration column. Gray bars and colored lines designate the analyzed fractions.
Molecular mass standards and the positions of the proteins are indicated. The asterisk indicates a degraded SUMO-CTR
fragment. (c) MALS analysis of the SIRT1CAT·CTR heterodimer. The differential refractive index is plotted against the elution
volume from a Superdex 200 10/300 GL gel-filtration column and overlaid with the determined molecular mass for the peak.
528 Structure of Human SIRT1possess excellent stereochemical parameters. The
models were refined to Rwork and Rfree values of
23.0% and 26.5% (apo form) and 16.8% and 18.9%
(quaternary complex), respectively. For details of the
data collection and refinement statistics, see Table 1.
Structural overview
The SIRT1 catalytic domain possesses the cano-
nical sirtuin fold as first described in the archaeal
Sir2·Af1·NAD+ complex structure [25], composed
of a larger NAD+-binding subdomain with a Ross-
mann fold and a smaller subdomain composed of ahelical module and a Zn2+-binding module, both of
which are insertions in the NAD+-binding domain.
The 25-residue CTR can be divided into a larger
N-terminal region, followed by a shorter C-terminal
extension, which each make distinct interactions with
the catalytic domain. The N-terminal region forms a β
hairpin that complements the central parallel β sheet of
the Rossmann fold domain with two additional strands.
This interface between the catalytic domain and the
CTR is large, hydrophobic, and highly conserved in
evolution. The C-terminal CTR extension forms addi-
tional contacts with the helical module that are only
observed in one of the two crystallized states.
Table 1. Crystallographic analysis
Data collection
Protein SIRT1CAT·CTR·
ADPR·Substrate
SIRT1CAT·CTR
apo
PDB code 4KXQ 4IG9
Synchrotron SSRL SSRL
Beamline BL12-2 BL12-2
Space group P3221 P43212
Cell parameters
a, b, c (Å) 92.7, 92.7, 97.7 115.8,
115.8, 350.5
α, β, γ (°) 90.0, 90.0, 120.0 90.0, 90.0, 90.0
Zn peak Zn peak
Wavelength (Å) 1.28210 1.2676
Resolution (Å) 50.0–1.85 50.0–2.65
Rsym (%)
a 4.3 (62.6) 8.8 (94.3)
〈I〉/〈σI〉a 34.3 (2.4) 18.3 (1.8)
Completeness (%)a 100.0 (99.9) 97.1 (92.8)
No. of observations 406,347 541,806
No. of unique reflections 80,328 (8010) 68,583 (6409)
Redundancy 5.1 (4.7) 7.9 (7.8)
Refinement
Resolution (Å) 50.0–1.85 50.0–2.65
No. of reflections total 80,282 67,954
No. of reflections test set 3824 (4.76%) 1982 (2.92%)
Rwork/Rfree (%) 16.8/18.9 23.0/26.5
No. of atoms 2842 9424
Protein 2484 9374
Ligand 47 4
Water 311 46
B-factors
Protein 39.4 30.3
Ligand 33.8 60.6
Water 45.1 8.2
RMSD
Bond lengths (Å) 0.009 0.002
Bond angles (°) 1.2 0.630
Ramachandran plotb (%)
Favored 97.7 96.1
Additionally allowed 2.3 3.9
Outliers 0.0 0.0
MolProbity score 1.11 2.04
a Values for the highest-resolution shell are shown in parentheses.
b As determined by MolProbity [62].
529Structure of Human SIRT1Despite the fact that we obtained crystals of
SIRT1CAT·CTR in the presence of NAD+, the
heterodimer is bound to adenosine diphosphate
ribose (ADPR), likely a product of non-enzymatic
NAD+ hydrolysis or disorder of the nicotinamide
moiety. Surprisingly, the heterodimer engages the
extended tail region of the catalytic domain of an
adjacent molecule in the crystal lattice, yielding a
quaternary substrate-mimicking complex. When
compared to the substrate- and cofactor-bound
state of the heterodimer, the apo form adopts a
wide-open conformation, in which the smaller sub-
domain undergoes a striking ~25° rotation, leading
to the disruption of all interactions between the large
and small subdomains and the formation of an
~15-Å-wide interdomain cleft. As such, we refer tothese two states as “open” and “closed” throughout
the text. This conformational change leads to the
exposure of the hydrophobic interior and the
cofactor-binding site of the enzyme in the open
state and to the disruption of the substrate-binding
groove.
Structure of the SIRT1 catalytic domain
The SIRT1 catalytic core is composed of 277
residues and is divided into two subdomains, a larger
NAD+-binding domain, which adopts aRossmann fold,
and a smaller domain, which is generated by two
insertions in the NAD+-binding domain, a helical
module (residues 269–324) and a Zn2+-binding
module (residues 362–419) (Fig. 2 and Fig. S1). The
NAD+-binding domain is composed of a central
six-stranded parallel β sheet (comprising strands
β1–β3 and β7–β9) and eight α helices (αA, αB, αG,
αH, and αJ–αM that pack against the β sheet core of
the domain) (Fig. 2 and Fig. S1). The helical module is
composed of four α helices (αC–αF), and the Zn2+-
bindingmodule is composedof threeβ strands (β4–β6)
and a single α helix (αI). The Zn2+ ion is tetrahedrally
coordinated by four invariant cysteine residues,
Cys371, Cys374, Cys395, and Cys398. An extensive
hydrophobic interface holds the helical and Zn2+-
binding modules together, generating the tightly
associated small subdomain of the catalytic core. In
total, 40 residues, primarily of helices αD, αE, and αF
and the αI–β6 region, are involved in the interaction
between the two modules, burying ~1800 Å2 of
surface area. The relative orientation and the interac-
tion between the large and small domains are
dramatically different in the open and closed states
and are described in detail below.
Interaction between SIRT1CAT and the CTR
The larger N-terminal region of the CTR (residues
641–653) forms a β hairpin that binds to the lower
edge of the NAD+-binding domain of SIRT1CAT,
complementing the central six-stranded parallel β
sheet of the Rossmann fold with two additional β
strands, β10 and β11 (Fig. 3). The β hairpin covers an
essentially invariant hydrophobic patch, which is
generated by residues of helices αA and αL, β strand
β9, and the β8–β9 connector, forming an entirely
hydrophobic interface that is composed of 17 and 11
residues of SIRT1CAT and CTR, respectively. In total,
the two proteins bury ~1150 Å2 of surface area. The
CTR-binding site on the Rossmann fold is located
close to the binding site for the adenine ring of NAD+
(termed the A pocket) and the CTR directly interacts
with Arg466 of the β8–β9 loop, which forms extensive
van der Waals contacts with one face of the adenine
ring (Fig. 3). CTR binding does not alter the
conformation of the catalytic domain, as evidenced
by a root-mean-square deviation (RMSD) of ~0.6 Å
Fig. 2. Structure of H. sapiens SIRT1. (a) Structure of the quaternary SIRT1CAT·CTR·ADPR·Substrate complex in
ribbon representation, colored as in Fig. 1a. (b) Structure of the SIRT1CAT·CTR heterodimer, displayed in the same
orientation as in (a). Views rotated 90° are shown on the right. See also Figs. S1 and S3.
530 Structure of Human SIRT1(276 Cα atoms) between the closed state and a
recently determined structure of the catalytic domain
in the absence of the CTR in complex with a small
molecule inhibitor (Fig. S2a) [39]. In the closed state,
the C-terminal extension of the CTR (residues 654–
660) undergoes a conformational change and forms
additional interactions with the helical module (see
below).Substrate interaction
To shed light on the conformational changes that
SIRT1 undergoes upon cofactor binding, we also
crystallized SIRT1CAT·CTR in the presence of
NAD+. While we were unable to obtain crystals of
SIRT1CAT·CTR in the presence of an acetylated
substrate peptide, the structure surprisingly revealed
Fig. 3. Interface between SIRT1CAT and the C-terminal regulatory segment. Ribbon representation of the interface
between the SIRT1CAT and the CTR colored according to Fig. 1a. The inset illustrates the position of the CTR-binding site
on the larger NAD+-binding domain and its interacting residues and is expanded on the right. Residues participating in the
interface are shown in a ball-and-stick representation.
531Structure of Human SIRT1that SIRT1CAT·CTR engages the extended seven-
residue tail segment (residues 504–510) of an
adjacent heterodimer in the crystal (Fig. 2 and Fig.
S3a). The sequence of the tail segment, PVKLSEI,
resembles the sequence and chemical nature of the
SIRT1 substrate region in p53, HKKAcLMF, but
possesses a hydrophobic leucine residue in place of
the substrate acetyl-lysine residue that is inserted
into the hydrophobic tunnel that leads to the internal
active site of the enzyme (Fig. 4). The tail region
binds SIRT1CAT·CTR by forming antiparallel
β-sheet-like interactions on one side with the
β7–αK connector (residues 444–446) of the Ross-
mann fold domain and on the other side with the
Phe-Gly-Glu (FGE) motif (residues 414–416) of the
Zn2+-binding module (Fig. 4a and b). While sub-
strate binding is primarily achieved by backbone
hydrogen bonding, the residues of both regions are
evolutionarily highly conserved, suggesting that
different substrates interact with SIRT1 in a similar
manner. Overall, the trans binding of the pseudo-
substrate tail region to SIRT1CAT·CTR faithfully
mimics the “β staple” interaction that was previously
observed in the structure of the non-physiological
ternary complex between the thermophilic bacterium
Thermotoga maritima TmSir2, ADPR, and a six-re-
sidue p53 peptide (Fig. 4) [29]. Confirmation of these
results will require additional structural analysis of a
SIRT1 substrate interaction.
While we crystallized SIRT1CAT·CTR in the
presence of NAD+, the electron density unambigu-
ously establishes that only the NAD+ hydrolysis
product ADPR, which lacks nicotinamide, is bound(Fig. 4c). The presence of ADPR may be the result
of slow non-enzymatic hydrolysis of NAD+ or
disorder of the nicotinamide moiety [49,50]. The
ADPR molecule is well ordered and makes exten-
sive hydrogen bond and van derWaals interactions
with the Rossmann fold domain, essentially iden-
tical with those seen in other previously determined
sirtuin structures [20,21,27,29,30,39,51].
In order to determine whether the trans interaction
between the tail region of one SIRT1CAT·CTRwith the
substrate-binding site of another SIRT1CAT·CTRmay
be physiologically relevant, we tested whether
SIRT1CAT·CTR is capable of forming dimers or other
higher-order oligomers in solution in the presence of
NAD+. A SEC–MALS analysis revealed that
SIRT1CAT·CTR remains monomeric in the presence
of 5 mM NAD+ with no higher-order oligomeric states
detectable at concentrations as high as 20 mg/ml (Fig.
S4). Further studies are required to address whether
the tail region is important for oligomerization and
regulation of SIRT1 in vivo, especially in the context of
the full-length protein and oligomeric substrates.
Conformational changes of SIRT1 upon cofactor
and substrate binding
We have determined the structure of human
SIRT1 in two different states, the apo form of
SIRT1CAT·CTR (open state) and a quaternary com-
plex of SIRT1CAT·CTRwith ADPR and a pseudo-sub-
strate peptide (closed state) (Fig. 2). The four copies of
the apo form in the asymmetric unit make different
crystal packing interactions and align with a maximum
Fig. 4. Structural comparison of H. sapiens SIRT1 to a bacterial Sir2 substrate complex. (a) A ribbon representation of
SIRT1CAT·CTR·ADPR·Substrate (left, colored as in Fig. 1a), T. maritima Sir2 in complex with a p53 peptide (middle), and
a superposition of the two (right). (b) A stick representation of the pseudo-substrate and p53 substrate peptide from the
corresponding structures in (a) and their superposition. The PDB code of the TmSir2 structure is 2H59 [29]. (c) Final 2|
Fo| − |Fc| electron density map around the ADPR and pseudo-substrate peptide rendered at 1.0 σ. See also Fig. S4.
532 Structure of Human SIRT1RMSD of ~0.5 Å2 over 286 Cα atoms, suggesting
that SIRT1 possesses a distinct open conformation
that is independent of crystal packing interactions
(Fig. S3b). Moreover, the tail region that engages an
adjacent SIRT1CAT·CTR in the closed state is
disordered in all four copies of the open state,
further demonstrating that it is not a structural
element of the catalytic core.A comparison between the open and closed states
reveals the conformational changes that SIRT1
undergoes upon substrate and cofactor binding.
The larger NAD+-binding domain, together with the
N-terminal region of the CTR, does not undergo any
major structural changes, as illustrated by an RMSD
of ~0.5 Å2 over 170 Cα atoms (Fig. 5). In the closed
state, the smaller domain forms an extensive interface
Fig. 5. Structural comparison of open and closed SIRT1 states. (a) Ribbon representations of the closed SIRT1-
CAT·CTR·ADPR·Substrate state, (b) the open SIRT1CAT·CTR conformation, and (c) a superposition of the two. (d and e)
Surface representations of the corresponding structures in (a) and (b). A view rotated 90° is shown on the right. (f) A model of
pseudo-substrate peptide and ADPR binding to the open SIRT1CAT·CTR state. A view rotated 90° is shown on the right. See
also Fig. S2.
533Structure of Human SIRT1with the larger domain, resulting in the complete
closure of the interdomain groove and the formation of
a hydrophobic tunnel that engages the substrate
residue (Fig. 5d). In the absence of cofactor and
substrate, SIRT1 adopts an open state with a large
interdomain groove, exposing the invariant hydro-
phobic interior and the NAD+-binding site (Fig. 5e and
f). Overall, the smaller domain rotates by ~25° with a
maximum displacement of the domain atoms of
~15 Å. Altogether, the two modules that generatethe small subdomain rotate essentially as a rigid body
with only minor changes to the backbone and side-
chain conformations as illustrated by an RMSD of
~1.3 Å2 over 114 Cα atoms. Notable exceptions are
the αB–αC interdomain connector and helix αC,which
undergo an additional conformational change to form
a lid over the cofactor, leading to its encapsulation,
and the FGE motif of the β6–αJ connector that forms
the upper β strand of the substrate-binding β staple.
The lower β strand of the β staple that is formed by the
Fig. 6. Mutational analysis. (a) Ribbon representation of the SIRT1CAT·CTR·ADPR·Substrate complex, with a stick
representation of all mutated active side residues. The Zn2+-binding module and helical module were removed for clarity.
(b) Ribbon representation of the SIRT1CAT·CTR·ADPR·Substrate complex, with a stick representation of all mutated
SIRT1CAT·CTR interface residues. (c) Deacetylase activity of SIRT1 proteins and mutants towards modified p53-based
peptides. Activity was determined in a luminescence (red) or fluorescence (blue) based assay and normalized against
wild-type SIRT1CAT activity. Each data point represents the mean of at least three independent measurements. Error bars
represent standard deviations. See also Fig. S5.
534 Structure of Human SIRT1β7–αK connector of the Rossmann fold only under-
goes minor conformational changes. Whereas the
N-terminal region of the CTR is static, the C-terminal
extension adopts a distinct conformation in the closed
state that allows for the formation of a salt bridge
between Glu656 and Arg276 of the helical module.
Taken together, SIRT1 undergoes dramatic con-
formational changes upon substrate and cofactor
binding. The open state observed here for SIRT1 is
substantially more open than previously determined
apo states of other sirtuins, suggesting that each
member of the sirtuin family adopts a unique open
state, while the closed states are essentially identical.Mutational analysis
To determine the importance of various residues
for the deacetylase activity of SIRT1, we generated
mutants based on the structures presented here, a
multispecies sequence alignment (Fig. S1), and
previous biochemical and structural work [18]. We
mutated seven residues in the SIRT1 active site that
are evolutionarily invariant in bacteria, archaea, and
eukaryotes and that have been shown in other sirtuins
to capture the nicotinamide released from the NAD+
cofactor (Ser265, Asn346, Ile347, and Asp348), to
bind and orient the NAD+ cofactor (Gln345), to
535Structure of Human SIRT1mediate the interaction with the substrate peptide
(Phe414), or that are catalytically required to
abstract a proton from the activated NAD+
(His363) (Fig. 6a). To clarify the role of the CTR in
SIRT1 regulation, we generated an additional five
mutants in the SIRT1CAT·CTR interface. These
included two residues of the catalytic domain that
contact both the CTR and the adenine ring of ADPR
(Arg466 and Asp481), two residues that form a salt
bridge between the catalytic domain and theCTR in the
closed conformation (Arg276 and Glu656), and a
truncation of the 12 C-terminal residues of the CTR
(CTRΔC) (Fig. 6b). Of the 12 mutants, 10 were
indistinguishable from the wild-type SIRT1CAT·CTR
heterodimer in their behavior on a gel-filtration column.
Two mutants, N346A and D348N, were insoluble
following recombinant expression and could thereforeFig. 7. Exchange of the C-terminal regulatory segment. (a) S
with SUMO-CTR. The analyzed proteins and complexes are in
formation, SUMO-CTR was mixed at approximately 2-fold mo
gel-filtration column. Gray bars and colored lines designate th
positions of the proteins are indicated. Untagged CTR is too
pull-downs of a preformed GST-CTR·SIRT1CAT complex with
pulled-down (bottom) samples are visualized by SDS-PAGE, f
the first two lanes of each gel contain the loaded samples of
amounts of GST-CTR·SIRT1CAT and SUMO-CTR, molecula
indicated. (c) CTR mutational analysis. His-tagged SIRT1CAT a
and the resulting soluble lysate fraction was analyzed in GST p
followed by Coomassie brilliant blue staining. Molecular mass
The asterisk indicates a degraded GST-CTR fragment.not be tested. The 10 SIRT1CAT·CTR mutants
(S265A, R276A, Q345A, I347A, H363A, F414A,
R466A, D481A, E656A, and CTRΔC) along with the
crystallized wild-type SIRT1CAT·CTR heterodimer and
SIRT1CAT in the absence of theCTRwere tested in two
different in vitrodeacetylaseactivity assays that employ
modified, acetylated p53-based peptides (Fig. S5). The
results of both assays were consistent and are sum-
marized in Fig. 6c.
All five active site mutants display either weak
(S265A) or no deacetylase activity (Q345A, I347A,
H363A, and F414A), demonstrating their involve-
ment in the catalytic reaction. These results are in
line with previous studies on other sirtuins and
support the previously proposed ADPR-peptidyl-
imidatemechanism for the deacetylation reaction [19].
The two mutants R466A and D481A, in which theEC interaction analysis of the SIRT1CAT·CTR heterodimer
dicated in each gel-filtration profile. For analysis of complex
lar excess and injected onto a Superdex 200 10/300 GL
e analyzed fractions. Molecular mass standards and the
small to be visualized on the SDS-PAGE gel. (b) GST
increasing amounts of SUMO-CTR. The loaded (top) and
ollowed by Coomassie brilliant blue staining. As reference,
GST-CTR·SIRT1CAT and SUMO-CTR. The relative molar
r mass standards, and the positions of the proteins are
nd GST-tagged CTR variants were coexpressed in E. coli,
ull-down assays. Samples were visualized by SDS-PAGE,
standards and the positions of the proteins are indicated.
536 Structure of Human SIRT1wild-type residues are sandwiched between the
ADPR and the C-terminal extension of the CTR,
yield proteins with substantially reduced catalytic
activity, highlighting their role in cofactor binding.
SIRT1CAT alone, being prone to aggregation,
showed variability in activity between experiments;
hence, any results obtained in the absence of CTR
need to be interpreted with caution. However,
despite its fragility, SIRT1CAT in isolation consis-
tently displayed higher activity compared to the
SIRT1CAT·CTR heterodimer, indicating an inhibitory
effect of the CTR. This effect is mediated by the 10
C-terminal residues of the CTR (CTRΔC), as
evidenced by the loss of SIRT1CAT inhibition in the
SIRT1CAT·CTRΔC heterodimer. Similar results were
obtained for the R276A and E656A mutants,
indicating that the salt bridge between these
residues is the primary determinant of inhibition by
the CTR. The R276A mutant did not significantly
increase the activity of SIRT1CAT in the absence of
the CTR, suggesting that the primary means through
which this residue regulates activity is through its
interaction with the CTR. Moreover, both Arg276 and
Glu656 are invariant in mammalian SIRT1 enzymes,
indicating that this regulatory feature is evolutionarily
conserved.Fig. 8. Thermostability assay. (a) SIRT1CAT was incub
non-interacting SUMO-CTRY650D, I651D mutant at the indicated
and supernatant fractions were visualized by SDS-PAGE, follo
standards and the positions of the proteins are indicated. (b) D
heterodimer under normal conditions (red) and following incuba
Activity was determined in a fluorescence-based assay and n
point represents the mean of at least three independent measur
of deacetylase activity is attributed to the aggregation of the cBiochemical analysis of the SIRT1CAT·CTR
interaction
As a result of the observed inhibitory effect of the
CTR on SIRT1 activity, we sought to determine
whether the CTR is a persistent structural feature of
the catalytic domain, as previously observed for the
tail region of the catalytic domain of S. cerevisiae Sir2
(Fig. S2b) [40]. Due to the fact that SIRT1CAT is prone
to aggregation, we were unable to determine the
dissociation constant between SIRT1CAT and the
CTR by isothermal titration calorimetry. However, we
tested whether the CTR can be displaced from the
SIRT1CAT·CTR complex. To test this hypothesis, we
incubated the SIRT1CAT·CTR heterodimer with
SUMO-tagged CTR and monitored exchange by
SEC. Indeed, a SUMO-CTR can displace the CTR
from a preformed SIRT1CAT·CTR complex (Fig. 7a).
We additionally incubated SUMO-CTR with a glu-
tathione S-transferase (GST)-CTR·SIRT1CAT com-
plex and performed pull-down experiments. Similarly,
increasing amounts of SUMO-CTR resulted in
decreasing amounts of pulled-down SIRT1CAT
(Fig. 7b). To further probe the SIRT1CAT·CTR
interaction, we designed mutations at the binding
interface and assayed their ability to form a complexated alone and in the presence of SUMO-CTR or a
temperatures for 1 h and pelleted by centrifugation. Pellet
wed by Coomassie brilliant blue staining. Molecular mass
eacetylase activity of SIRT1CAT and the SIRT1CAT·CTR
tion at 37 °C for approximately 2 h prior to the assay (blue).
ormalized against wild-type SIRT1CAT activity. Each data
ements. Error bars represent standard deviations. The loss
atalytic domain.
537Structure of Human SIRT1in a GST pull-down assay (Fig. 7c). Mutation of three
hydrophobic CTR residues (Phe644, Tyr650, and
Ile651) to alanine or aspartate abolished CTR binding
to SIRT1CAT. Mutation of Tyr642 to alanine resulted in
reduced binding that was completely lost upon muta-
tion to aspartate. Based on these results, we conclude
that the CTR binding may represent a regulated
interaction to inhibit SIRT1 activity.
Thermostability
During our in vitro deacetylation assays, wenoticed
a rapid decay of enzymatic activity and a variability
between different purifications for SIRT1CAT, which
was not observed for SIRT1CAT·CTR. In addition, we
obtained substantially lower yields for SIRT1CAT in
isolation relative to the coexpressed SIRT1CAT·CTR
complex (Table S2). These findings prompted us to
explore whether the CTR stabilizes the catalytic
domain. We found that the SIRT1CAT·CTR hetero-
dimer was substantially more resistant to temperature
denaturation than SIRT1CAT in isolation or in the
presence of a non-interacting CTR mutant. Specifi-
cally, whereas SIRT1CAT already begins to precipitate
at 30 °C, the SIRT1CAT·CTR heterodimer remains
completely soluble up to 39 °C (Fig. 8a). In line with
these results, the isolated SIRT1 catalytic domain
displays an almost complete loss of activity when
incubated for 2 h at 37 °C, whereas activity is
maintained for the SIRT1CAT·CTR heterodimer
(Fig. 8b). These data support a stabilizing role for
theCTRon theSIRT1catalytic domainand provide an
explanation for previous difficulties in characterizing
the biochemical and structural properties of SIRT1.Discussion
We have determined the crystal structure of the
catalytic domain of human SIRT1 in complex with a
C-terminal regulatory segment (CTR) in two different
conformations, the apo form of the heterodimer and
a quaternary complex with ADPR and a pseudo-
substrate, the tail of another SIRT1CAT that mimics a
p53 substrate sequence. The comparison of the two
structures reveals that the interdomain angle and
association between the two domains of the catalytic
core are dramatically different upon substrate and
cofactor binding. Further conformational changes
occur in the C-terminal extension of the CTR that
inhibit the activity of the catalytic domain.
The observation that sirtuins engageunique regions
flanking the canonical catalytic domain has been
made previously in the structure of S. cerevisiae Hst2
[26]. In that case, a homotrimer has been observed in
the crystal and in solution, which is mediated by an
N-terminal region that interacts with an adjacent
catalytic domain in a substrate-mimicking fashion. In
human SIRT1, a C-terminal seven-residue tail seg-ment that is disordered in the apo state engages an
adjacent molecule in the NAD+-bound closed state.
The overall mode of interaction faithfully mimics the
interaction between a p53 substrate peptide, and the
main difference is that a hydrophobic leucine residue,
instead of an acetylated lysine residue, is inserted into
the hydrophobic tunnel that leads to the internal active
site of the enzyme. The substrate-mimicking interac-
tion observed here might be useful for the develop-
ment of competitive SIRT1 inhibitors.
Our biochemical analysis expands upon recent
findings on the regulatory nature of the CTR [47,48].
Namely, we establish an inhibitory role for the CTR
primarily mediated by the formation of a salt
bridge between the C-terminal extension and the
helical module that is only observed in our closed
SIRT1CAT·CTR·ADPR·Substrate structure. We pro-
pose that this interaction tunes the activity of the
catalytic domain by influencing the conformational
changes that are required for substrate and cofactor
turnover (Fig. 9). This is in contrast to recent work
stating that the CTR is required for SIRT1 activity [47].
However, we believe that this conclusion may be a
result of the propensity of the SIRT1CAT to aggregate
in solution in the absence of the CTR. Despite the
overall hydrophobic nature and large surface of the
SIRT1CAT·CTR interface, we demonstrate that the
SIRT1CAT·CTR interaction is not merely a structural
augmentation of the catalytic domain, but rather, it
possesses the necessary characteristics of a regu-
lated interaction. Such a regulatory mechanism could
involve the phosphorylation of the CTR, which
contains four predicted phosphorylation sites
(Tyr650, Tyr658, Ser659, and Ser661) [52].
Our structural and functional analysis presented
here allow us to propose a model for the regulation
of SIRT1 and provide the framework for the
development of potent and selective SIRT1 activity
modulators that promise to be a new therapeutic
avenue for the treatment of a variety of human
diseases.Materials and Methods
Protein expression and purificationDNA fragments of H. sapiens SIRT1 were amplified by
PCR and cloned into the vector pGEX-6P-1 (GE Health-
care), a modified pET28a vector (Novagen) that contained
a PreScission protease site after the N-terminal hexahis-
tidine tag (pET28a-PreS) [53], and a modified pET28b
vector that contained an N-terminal hexahistidine-SUMO
tag (pET28b-SUMO) [54]. SIRT1 mutants were generated
by QuikChange mutagenesis (Stratagene) and confirmed
by DNA sequencing. Details of all constructs are listed in
Table S1.
All proteins were expressed in Escherichia coli
BL21-CodonPlus(DE3)-RIL cells (Stratagene) grown in LB
Fig. 9. Model for the conformational changes and regulation of SIRT1. A cartoon representation of the apoSIRT1CAT·CTR
heterodimer (left) and the SIRT1CAT·CTR·ADPR·Substrate complex (right), colored as in Fig. 1a. Substrate and cofactor
binding leads to the closure of the SIRT1 catalytic domain. The substrate peptide is primarily bound by backbone interactions
and the formation of a three-stranded antiparallel β staple. The hydrophobic acetylated lysine substrate residue reaches into
the secluded internal active site through the hydrophobic tunnel where it is oriented in close proximity to the activatedNAD+. In
the closed state, the CTR forms a salt bridge with the helical module, thereby reducing the efficiency of catalysis.
538 Structure of Human SIRT1media supplemented with appropriate antibiotics. Protein
expression was induced at an OD600 of approximately 0.6
with 500 μM IPTG for 16–18 h at 18 °C. Cells were
harvested by centrifugation.
The SIRT1CAT·CTR complex and all SIRT1CAT·CTR
mutants were made by coexpressing SIRT1CAT in
pET28a-PreS and CTR in pGEX-6P-1 (Table S2). Cells
were resuspended in a buffer containing 20 mM Tris
(pH 8.0), 100 mM NaCl, 5 mM DTT, 2 μM bovine lung
aprotinin (Sigma), and complete ethylenediaminetetraaceti-
c-acid-free protease inhibitor cocktail (Roche) and were
flash frozen in liquid nitrogen. Thawedcellswere lysedwith a
cell disrupter (Avestin), and the lysate was centrifuged for
1 h at 40,000g. The cleared lysate was applied to a
glutathione Sepharose column equilibrated in 20 mM Tris
(pH 8.0), 100 mM NaCl, and 5 mM DTT (GE Healthcare)
and was eluted via a glutathione gradient. Pooled fractions
were cleavedwith PreScission protease (GEHealthcare) for
12 h and further purified over an additional glutathione
Sepharose column. The protein was concentrated and
injected onto a HiLoad 16/60 Superdex 75 column (GE
Healthcare) equilibrated in 20 mM Tris (pH 8.0), 100 mM
NaCl, and 5 mM DTT. Pooled fractions were concentrated
to 12.5 mg/ml andused in subsequent crystallization trials or
for in vitro activity assays. The GST-tagged SIRT1CAT·CTR
used in pull-down experiments was purified in the same
manner, omitting the protease cleavage step.
SIRT1CAT in isolation and all SIRT1CAT mutants were
made by expressing SIRT1CAT in pET28a-PreS. Cells were
resuspended in a buffer containing 20 mM Tris (pH 8.0),
500 mM NaCl, 5 mM β-mercaptoethanol, 2 μM bovine lung
aprotinin (Sigma), and complete ethylenediaminetetraaceti-
c-acid-free protease inhibitor cocktail (Roche) and were
flash frozen in liquid nitrogen. Thawedcellswere lysedwith a
cell disrupter, and the lysate was centrifuged for 1 h at
40,000g. The cleared lysate was loaded onto a Ni-NTA
column (Qiagen) and eluted via an imidazole gradient.
Protein-containing fractions were pooled; dialyzed against a
buffer containing 20 mM Tris (pH 8.0), 100 mM NaCl, and
5 mMDTT; and cleaved with PreScission protease for 12 h.
Cleaved protein was bound to a HiTrap Q HP (GEHealthcare) column, eluted via a NaCl gradient, concen-
trated, and injected onto a HiLoad 16/60 Superdex 75
column equilibrated in 20 mM Tris (pH 8.0), 100 mM NaCl,
and 5 mM DTT. SUMO-CTR, and all SUMO-CTR mutants,
followed the same purification as SIRT1CAT in isolation.
Structure determination and refinement
Crystals of SIRT1CAT·CTR were grown at 21 °C in
hanging drops containing 1 μl of the protein and 1 μl of a
reservoir solution consisting of 100 mM Tris (pH 7.4) and
11% polyethylene glycol 20,000. Crystals grew in the
tetragonal space group P43212 and reached a maximum
size of approximately 700 μm × 100 μm × 100 μm within a
week. Crystals of SIRT1CAT·CTR·ADPRwere grownunder
similar conditions in the presence of a 2-foldmolar excess of
NAD+ (Sigma), grew in the trigonal space group P3221, and
reached a max imum s ize o f app rox ima te l y
300 μm × 100 μm × 100 μm within 2 weeks. For cryo
protection, crystals were stabilized in 100 mM Tris
(pH 7.4), 13% polyethylene glycol 20,000, and 20%
ethylene glycol (added in 1% increments). X-ray diffraction
data were collected at 100 K at beamline 12-2 at the
Stanford Synchrotron Radiation Lightsource (SSRL) and at
beamline 8.2.2 at the Advanced Light Source at Lawrence
Berkeley National Laboratory. X-ray intensities were pro-
cessed using the HKL2000 denzo/scalepack package [55].
Both structures were solved by single-wavelength anom-
alous dispersion using X-ray diffraction data collected
utilizing the anomalous scattering of the endogenous Zn2+
ions. Heavy metal sites were identified with SHELXD [56].
Phases were calculated in SHARP [57], followed by density
modification in DM [58] with solvent flattening, histogram
matching, and NCS averaging. This procedure yielded
excellent electron density maps that allowed for the
placement of the coordinates of the S. cerevisiae Sir2
(PDB code 2HJH). Iterative rounds of model building and
refinement in Coot [59] and PHENIX [60] yielded final
models in which all residues of both protein fragments were
resolved in the substrate- and cofactor-bound stateswith the
539Structure of Human SIRT1exception of the C-terminal tails of the catalytic domain
(residues 503–510; apo state) and CTR (residues 661–665;
both states). The final Rwork and Rfree values of the apo and
the substrate- and cofactor-bound states of SIRT1 were
23.0% and 26.5% and 15.6% and 18.7%, respectively. Both
models possess excellent stereochemical parameters with
no residues in the generously allowed or disallowed regions
of the Ramachandran plot as assessed with PROCHECK
andMolProbity [61,62]. For details of the data collection and
refinement statistics, see Table 1.
Analytical SEC
Protein interaction experiments were carried out on a
Superdex 200 10/300 GL gel-filtration column (GE Health-
care) equilibrated in a buffer containing 20 mMTris (pH 8.0),
100 mM NaCl, and 5 mM DTT. SIRT1CAT and the SIRT1-
CAT·CTR heterodimer were mixed with an approximately
2-fold molar excess of SUMO-tagged CTR and were
incubated for 30 min on ice. Complex formation was
monitored by injection of the preincubated proteins and the
individual components in isolation and was confirmed by
SDS-PAGE of the protein-containing fractions, followed by
Coomassie brilliant blue staining.
GST pull-down assays
12.5 μg of a GST-CTR·SIRT1CAT complex was mixed
with varying amounts of SUMO-CTR, added to approxi-
mately 20 μl of glutathione Sepharose beads (GE Health-
care) equilibrated in a buffer containing 20 mM Tris
(pH 8.0), 100 mM NaCl, and 5 mM DTT and incubated
on ice for 1 h. The beads were isolated via centrifugation at
750g and were washed five times by resuspension in
200 μl of buffer, followed by subsequent centrifugation. All
samples were analyzed by SDS-PAGE, followed by
Coomassie brilliant blue staining. For CTR mutational
analysis, lysate from E. coli transformed with the indicated
constructs was added to 250 μl of beads.
Deacetylase activity assays
Deacetylase activity of SIRT1 proteins was determined
using the SIRT-Glo (Promega) and Fluor de Lys SIRT1
(Enzo) assays, according to the manufacturers' protocols.
SIRT-Glo reactions were carried out with 1 μM pure protein
and were incubated at room temperature for 45 min. Fluor
de Lys reactions contained 0.2 μM pure protein, 75 μM
substrate, and 3 mM NAD+; were incubated at 37 °C for
45 min; and were developed at room temperature for 1 h.
Luminescence (SIRT-Glo) and fluorescence (Fluor de Lys)
were measured using a Flexstation-3 microplate reader
(Molecular Devices) and autofluorescence was subtracted.
Thermostability assay
15 μg of SIRT1CAT in isolation or mixed with an
approximately 2-fold molar excess of SUMO-CTR or
SUMO-CTRY650D, I651D was incubated at the indicated
temperatures for 1 h. Samples were pelleted by centrifu-
gation at 30,000g and analyzed by SDS-PAGE followed by
Coomassie brilliant blue staining.Multiangle light scattering
Purified proteins were characterized by MALS following
SEC [63]. Proteins were injected onto a Superdex 200 10/
300 GL gel-filtration chromatography column equilibrated
in a buffer containing 20 mM Tris (pH 8.0), 100 mM NaCl,
and 5 mM DTT. The chromatography system was con-
nected in series with an 18-angle light-scattering detector
(DAWN HELEOS II; Wyatt Technology), a dynamic light-
scattering detector (DynaPro Nanostar; Wyatt Technol-
ogy), and a refractive index detector (Optilab t-rEX; Wyatt
Technology). Data were collected every 1 s at a flow rate
of 0.5 ml/min at 25 °C. Data analysis was carried out using
the program ASTRA 6, yielding the molar mass and mass
distribution (polydispersity) of the sample.
Illustration and figures
The sequence alignment of SIRT1 was generated using
ClustalX and colored with ALSCRIPT [64,65]. Figures were
generated using PyMOL†. Electrostatic potential was calcu-
lated with APBS (Adaptive Poisson–Boltzmann Solver) soft-
ware [66].
Accession numbers
The atomic coordinates and structure factors of the
H. sapiens SIRT1CAT·CTR heterodimer and the quaternary
SIRT1CAT·CTR·ADPR·Substrate complex have been
deposited in the Protein Data Bank under accession codes
4IG9 and 4KXQ.
Supplementary data to this article can be found online at
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